We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+9.96%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.79B
AUM Growth
-$56M
Cap. Flow
-$584M
Cap. Flow %
-20.93%
Top 10 Hldgs %
31.86%
Holding
129
New
19
Increased
19
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$67.9M
2
XENT
Intersect ENT, Inc
XENT
+$33.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$32.9M
4
NVRO
NEVRO CORP.
NVRO
+$32.8M
5
ACHC icon
Acadia Healthcare
ACHC
+$27.2M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$130M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$80M
3
AET
Aetna Inc
AET
+$42M
4
CVS icon
CVS Health
CVS
+$39.3M
5
WBA
Walgreens Boots Alliance
WBA
+$31.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.65%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTHX
51
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$15M 0.54%
287,000
– –
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
$14.9M 0.53%
1,343,181
– –
KALV
53
DELISTED
KalVista Pharmaceuticals
KALV
$14.4M 0.51%
+650,000
New +$8.79M
SIEN
54
DELISTED
Sientra, Inc.
SIEN
$14.2M 0.51%
59,377
-5,533
-9% -$1.21M
AAC
55
DELISTED
AAC Holdings
AAC
$14.1M 0.51%
1,853,998
– –
CTMX icon
56
CytomX Therapeutics
CTMX
$771M
$13.5M 0.48%
729,948
– –
TNDM icon
57
Tandem Diabetes Care
TNDM
$1.22B
$12.1M 0.43%
283,115
-2,290,190
-89% -$80M
AVDL
58
DELISTED
Avadel Pharmaceuticals
AVDL
$12M 0.43%
2,722,241
– –
NVTA
59
DELISTED
Invitae Corporation
NVTA
$11.5M 0.41%
688,062
-1,213,726
-64% -$13.8M
RYTM icon
60
Rhythm Pharmaceuticals
RYTM
$7.24B
$10.7M 0.38%
365,689
-337,911
-48% -$10.7M
NITE
61
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$10.2M 0.37%
+499,747
New +$10.3M
ALLK
62
DELISTED
Allakos
ALLK
$10.1M 0.36%
+225,000
New +$9.23M
MLNT
63
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$9.13M 0.33%
462,372
-336,789
-42% -$8.51M
BHVN
64
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.97M 0.32%
239,000
-159,000
-40% -$5.85M
BLUE
65
DELISTED
bluebird bio
BLUE
$8.97M 0.32%
4,743
-3,981
-46% -$8.22M
LIVN icon
66
LivaNova
LIVN
$4.41B
$8.86M 0.32%
+71,500
New +$8.43M
QURE icon
67
uniQure
QURE
$2.77B
$8.79M 0.31%
+241,430
New +$8.98M
KPTI icon
68
Karyopharm Therapeutics
KPTI
$156M
$8.09M 0.29%
+31,667
New +$8.75M
VKTX icon
69
Viking Therapeutics
VKTX
$4.28B
$8.01M 0.29%
+460,000
New +$5.47M
INSP icon
70
Inspire Medical Systems
INSP
$1.5B
$7.95M 0.28%
+189,000
New +$8.87M
AUTL
71
Autolus Therapeutics
AUTL
$375M
$7.67M 0.27%
250,000
– –
RARX
72
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$6.92M 0.25%
382,700
– –
RCKT icon
73
Rocket Pharmaceuticals
RCKT
$378M
$6.89M 0.25%
280,000
– –
NVTR
74
DELISTED
Nuvectra Corporation Common Stock
NVTR
$6.13M 0.22%
278,890
+147,890
+113% +$2.85M
ALIM
75
DELISTED
Alimera Sciences
ALIM
$5.93M 0.21%
403,529
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2018 Portfolio in Review

As of Q3 2018, Deerfield Management held 129 positions worth $2.79B, down 2% from $2.85B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $584M in Q3 2018, closing 26 positions and reducing 27 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $130M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 74% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $29.9M.

  • Deerfield Management's largest Q3 2018 buy was NEVRO CORP.: 525,040 shares worth $29.9M.
  • Deerfield Management added most to Aerie Pharmaceuticals in Q3 2018, an estimated $67.9M increase.
  • Deerfield Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $80M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2018, selling an estimated $130M.
  • Deerfield Management's ten largest holdings make up 32% of its $2.79B portfolio in Q3 2018.
  • Deerfield Management opened 19 new positions and closed 26 in Q3 2018.
  • Deerfield Management's portfolio value fell 2% quarter-over-quarter to $2.79B.

Based on Deerfield Management's 13F filing for Q3 2018, filed 14 Nov 2018.